Skip to main content

Table 7 Readmissions within 90 Days of Discharge

From: Efficacy and safety of aerosol inhalation of recombinant human interferon α1b (IFNα1b) injection for noninfluenza viral pneumonia, a multicenter, randomized, double-blind, placebo-controlled trial

ItemIFN α1b GroupControl GroupIFN α1b GroupControl Group
Readmission within 90 days of discharge5 (6.6%)4 (4.6%)5 (7.2%)4 (4.9%)
No readmission within 90 days of discharge71 (93.4%)83 (95.4%)64 (92.8%)78 (95.1%)
Total (Missing)76 (0)87 (0)69 (0)82 (0)
StatisticsFisher’s exact probability testFisher’s exact probability test